The blood-brain barrier is the primary obstacle to efficient intracerebral drug delivery. Focused ultrasound, in conjunction with microbubbles, is a targeted and non-invasive way to disrupt the blood-brain barrier. Many commercially available ultrasound contrast agents and agents specifically designed for therapeutic purposes have been investigated in ultrasound-mediated blood-brain barrier opening studies. The new generation of sono-sensitive agents, such as liquid-core droplets, can also potentially disrupt the blood-brain barrier after their ultrasound-induced vaporization. In this review, we describe the different compositions of agents used for ultrasound-mediated blood-brain barrier opening in recent studies, and we discuss the challenges of the past five years related to the optimal formulation of agents.
Dauba, A., Delalande, A., Kamimura, H., Conti, A., Larrat, B., Tsapis, N., et al. (2020). Recent advances on ultrasound contrast agents for blood-brain barrier opening with focused ultrasound. PHARMACEUTICS, 12(11), 1-30 [10.3390/pharmaceutics12111125].
Recent advances on ultrasound contrast agents for blood-brain barrier opening with focused ultrasound
Conti A.;
2020-11-01
Abstract
The blood-brain barrier is the primary obstacle to efficient intracerebral drug delivery. Focused ultrasound, in conjunction with microbubbles, is a targeted and non-invasive way to disrupt the blood-brain barrier. Many commercially available ultrasound contrast agents and agents specifically designed for therapeutic purposes have been investigated in ultrasound-mediated blood-brain barrier opening studies. The new generation of sono-sensitive agents, such as liquid-core droplets, can also potentially disrupt the blood-brain barrier after their ultrasound-induced vaporization. In this review, we describe the different compositions of agents used for ultrasound-mediated blood-brain barrier opening in recent studies, and we discuss the challenges of the past five years related to the optimal formulation of agents.| File | Dimensione | Formato | |
|---|---|---|---|
|
pharmaceutics-12-01125.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
2.67 MB
Formato
Adobe PDF
|
2.67 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
